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A
 new
 drug delivery m
ethod for infants is presented w
hich incorporates an active pharm
aceutical 
ingredient (A
PI)-loaded insert into a N
ipple Shield D
elivery System
 (N
SD
S). The A
PI is released directly 
into m
ilk during breastfeeding. This study investigates the feasibility of using the N
SD
S to deliver the 
m
icrobicide sodium
 dodecyl sulfate (SD
S), w
ith the goal of preventing m
other-to-child transm
ission 
(M
TCT) of H
IV
 during breastfeeding in low
-resource settings, w
hen there is no safer alternative for the 
25 
infant but to breastfeed. SD
S has been previously show
n to effectively inactivate H
IV
 in hum
an m
ilk. A
n 
apparatus w
as developed to sim
ulate m
ilk flow
 through and drug release from
 a N
SD
S. U
sing this 
apparatus m
ilk w
as pulsed through a prototype device containing a non-w
oven fiber insert im
pregnated 
w
ith SD
S and the m
icrobicide w
as rapidly released. The total SD
S release from
 inserts ranged from
  
70-100%
 of the average 0.07 g load w
ithin 50 m
l (the volum
e of a typical breastfeed). H
um
an m
ilk spiked 
30 
w
ith H
9/H
IV
IIIB cells w
as also passed through the sam
e set-up. G
reater than 99%
 reduction of cell-
associated H
IV
 infectivity w
as achieved in the first 10 m
l of m
ilk. This proof of concept study 
dem
onstrates efficient drug delivery to breastfeeding infants is achievable using the N
SD
S. 
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1. IN
TR
O
D
U
C
TIO
N
  
There is no single suitable drug and nutrient delivery m
ethod available for infants or young children 
(K
earns et al., 2003). In developing countries w
here m
edical infrastructure is often scarce, pediatric drug 
and nutrient delivery system
s face num
erous challenges in supply, stability, sterility, distribution, and 
50 
dosing (K
noppert, 2009; W
H
O
, 2010c). Liquid form
ulations are often the principal m
ethod of pediatric 
drug delivery, but are ill-adapted due to high-cost and lack of access to refrigeration or potable w
ater for 
reconstitution (U
N
IC
EF and W
H
O
, 2010). W
hen liquid form
ulations are not available, a solid dosage form
 
is often the only available m
ethod for adm
inistration of m
edicine. M
any current m
edicines are only 
available in adult strength, so safe and accurate dosing for an infant is com
plicated  
55 
(Pandolfini and B
onati, 2005; Stoltenberg et al., 2010).  A
dditionally, liquid form
ulations can be 
unpalatable especially for young infants and m
ay require undesirable toxic excipients, such as preservatives 
and solvents. There is a clear need for form
ulations that are appropriate, safe, and effective for children. 
O
ne clear exam
ple of the need for appropriate m
edicines to infants in developing countries is the 
prevention of m
other-to-child transm
ission (M
TCT) of H
IV
 in breastfeeding. O
f the approxim
ately 
60 
500,000 infants per year w
ho are infected w
ith H
IV
 from
 their m
others, it is estim
ated that 200,000 infants 
are infected through breastfeeding (C
hasela et al., 2010), w
ith 90%
 of M
TCT occurring in Sub-Saharan 
A
frica (U
N
A
ID
S, 2008). W
H
O
 policy on breastfeeding states that, ‘…
w
hen replacem
ent feeding is 
acceptable, feasible, affordable, sustainable and safe, avoidance of all breastfeeding by H
IV
 infected 
m
others is recom
m
ended...’(W
H
O
, 2010b). This condition is often not m
et, and breastfeeding in  
65 
low
-resource settings has been show
n to significantly increase infant survival (B
rahm
bhatt and G
ray, 
2003). In light of this, recent W
H
O
 guidelines recom
m
end the continued use of oral anti-retroviral (A
RV
) 
drugs by the m
other and/or the infant to prevent H
IV
 transm
ission through breastfeeding (W
H
O
, 2010a). 
H
ow
ever, w
idespread distribution of A
R
V
s does not yet exist in Sub-Saharan A
frica and A
RV
 use can lead 
to side effects and resistant strains of the virus if infection still occurs (Zeh et al., 2011).  
70 
A
s an alternative approach, the adm
inistration of edible m
icrobicides into expressed infected m
ilk w
hich is 
then delivered to the baby has been previously considered (H
artm
ann et al., 2006a). Sodium
 dodecyl (or 
lauryl) sulfate (SD
S), an anionic surfactant, is a candidate for use as an edible m
icrobicide w
ith anti-H
IV
 
activity in hum
an m
ilk. It has been dem
onstrated that 0.1 – 1 w
t%
 SD
S rapidly kills sexually transm
itted 
pathogens, including H
IV
 in m
edia (H
ow
ett et al., 2000, 1999; K
rebs et al., 2000, 1999). A
 concentration 
75 
of 0.1 w
t%
 SD
S has been dem
onstrated to rapidly inactivate cell free and cell-associated H
IV
 in hum
an 
m
ilk (H
artm
ann et al., 2005; Tuaillon et al., 2009).  This concentration is safe for infant use, based on a 
m
axim
um
 acceptable infant oral exposure to SD
S of 1 g/kg (of infant)/day and an biochem
ical analysis of 
the effect of SD
S on m
ilk content (H
artm
ann et al., 2006a, 2006b).  A
nother benefit of SD
S is its broad 
antiviral activity by solubilizing lipid m
em
branes; therefore unlike m
any anti-viral com
pounds SD
S is 
80 
strain independent and unlikely to drive H
IV
 m
utation to a resistant form
 (H
artm
ann et al., 2006b).  
G
iven that delivery of SD
S during breastfeeding m
ay be an effective m
ethod of reducing viral load in m
ilk 
and preventing M
TCT of H
IV
, w
e propose a new
 m
ethod to deliver SD
S to infants during breastfeeding 
that also overcom
es m
any of the general challenges associated w
ith frequent drug delivery to infants. The 
concept is to incorporate a drug-im
pregnated insert into a nipple shield w
orn by a m
other during 
85 
breastfeeding (Fig. 1), w
here during suckling, a drug is released directly into the m
ilk (G
errard, 2011; 
Sokal et al., 2009). N
ipple shields, typically a single m
olding of silicone, are available at low
 cost and are 
used to aid m
others and/or infants during breastfeeding, typically to reduce pain or nipple dam
age, or to 
assist latching on (R
iordan, 2005). The N
SD
S w
ould have an insert containing a dose of the A
PI in dried 
form
. In the studies reported in this publication, N
SD
S inserts w
ere m
ade from
 non-w
oven fiber, 
90 
representing a flexible, high surface area support for drug incorporation. The m
other w
ould w
ear the N
SD
S 
as her child breastfeeds, and as m
ilk passes through the insert the A
PI w
ould be released directly into the 
m
ilk and pass to the infant. The insert could be placed inside the N
SD
S prior to each feed or the N
SD
S 
could be preloaded w
ith the insert prior to the m
other obtaining the device, and be entirely disposable after 
one use. A
lternatively, the N
SD
S could be w
ashed, disinfected, and reloaded w
ith another insert for reuse.  
95 
This study had tw
o aim
s: firstly to determ
ine the kinetics of drug release into m
ilk from
 a N
SD
S insert 
during a pulsed flow
 that m
im
ics breastfeeding; and secondly to establish w
hether the release of SD
S from
 
a N
SD
S into hum
an m
ilk can inactivate H
IV
 w
ithin the fluid.  
2. M
A
TER
IA
LS A
N
D
 M
ETH
O
D
S 
2.1 Form
ulation of non-w
oven fiber inserts w
ith SD
S 
100 
To m
ake the N
SD
S inserts, 10 m
m
 diam
eter discs of a m
edical grade non-w
oven cellulosic (viscose) and 
polyester based fiber m
atrix w
ith a 2.75 m
m
 thickness and area density of 300 g/m
2 (B
athfelt, Texel, 
Q
uébec, C
anada) w
ere soaked in a 30 w
t%
 SD
S (R
eagent Plus > 98.5%
 purity, Sigm
a A
ldrich, U
K
) 
solution at 60 °C
 for 10 seconds. They w
ere then air dried at room
 tem
perature on a m
esh. A
fter 72 hours 
drying their w
eight stabilized w
ith a final w
eight gain of 0.07 g (standard deviation 0.01 g, n = 13). This 
105 
fiber grade w
as chosen because it is non-toxic, suitable for flow
 w
ith low
 back pressure, and it is easy to 
load a com
pound such as SD
S onto it. 
2.2 K
inetics of SD
S release into m
ilk in sim
ulated breastfeeding conditions 
To sim
ulate use of a N
SD
S to deliver SD
S during breastfeeding, loaded inserts w
ere placed in an O
-ring 
(B
S012 V
iton TM O
-ring, 3/8 ” ID
, U
K
) to seal them
 into a Sinnex filter holder (M
illipore, M
A
, U
SA
) (Fig. 
110 
2 a-c), or w
eighed am
ounts of SD
S pow
der w
ere placed directly into the holder (0.1 g). Sam
ple fluids w
ere 
passed through a peristaltic pum
p (M
asterflex console drive, easy load 11 M
asterflex L/S m
odel 77200-50, 
C
ole Palm
er, U
K
), heated to 37 °C
 by passing through tubing in a w
ater bath held at 42 °C
, and then 
delivered through the SD
S loaded device. A
round 50 x 1 m
l fractions per test w
ere collected from
 the flow
-
through using a SuperFrac
TM fraction collector (G
E H
ealthcare Sciences, U
K
) to reflect typical am
ounts of 
115 
m
ilk consum
ed in a feed (K
ent et al., 2006). The m
ilk reservoir w
as continuously stirred to prevent fat 
accum
ulating at the top inlet. Individual fractions w
ere assayed in triplicate for SD
S concentration using a 
colorim
etric assay described below
.  
SD
S concentration in m
ilk fractions w
as m
easured using an adapted stains-all colorim
etric assay (R
usconi 
et al., 2001). The assay relies on the shift in absorbance at 438 nm
 w
hen the reagent dye, stains-all, is 
120 
m
ixed w
ith SD
S. The stains-all reagent underw
ent a spectral shift w
hen m
ixed w
ith m
ilk alone w
ithout 
SD
S, presum
ably caused by interactions w
ith lipids, proteins or com
ponents w
ith surfactant-like properties 
in m
ilk. H
ow
ever, a highly reproducible further spectral shift w
as seen w
hen SD
S w
as added. Thus, by 
diluting m
ilk sam
ples to a fixed ratio in w
ater prior to testing, keeping the absorbance signal caused by 
m
ilk alone constant, the absorbance at 438nm
 w
as still directly proportional to SD
S concentration, allow
ing 
125 
rapid and sim
ple SD
S m
easurem
ent in m
ilk (Fig. 3). A
 range of dilution factors w
ere used to accurately 
detect concentrations of SD
S in m
ilk above 0.03 w
t%
. SD
S concentration in test sam
ples w
as calculated by 
com
parison to calibration curves m
easured at the sam
e sam
ple dilution, using standard SD
S solutions m
ade 
in identical m
ilk from
 a continuously stirred 5%
 w
t/vol. (m
ilk) SD
S stock solution. Fluids used w
ere: cow
’s 
m
ilk, either pasteurized but not hom
ogenized (Taste the D
ifference Jersey M
ilk, 5.2%
 fat, J.S. Sainsbury’s, 
130 
C
am
bridge,  U
K
), pasteurized and hom
ogenized (W
hole m
ilk, 3.6%
 fat, J.S. Sainsbury’s, C
am
bridge, U
K
), 
or unpasteurized non-hom
ogenized full-fat goat’s m
ilk (4%
 fat, W
obbly B
ottom
 Farm
, H
itchin, 
H
ertfordshire, U
K
). 
To m
ake an assay solution sufficient to analyze 250 sam
ples, 20 m
g stains-all dye (Sigm
a-A
ldrich, U
K
) 
w
as dissolved in 1 m
l follow
ed by a further 19 m
l of 1:1 isopropanol:w
ater, follow
ed by dilution w
ith 
135 
w
ater to a total volum
e of 380 m
l plus the addition of 20 m
l form
am
ide and thorough m
ixing for 30 
seconds. U
nknow
n m
ilk sam
ples w
ere thoroughly m
ixed and diluted to 1:2.5, 1:10 or 1:100 by volum
e 
w
ith ultrapure M
illiQ
 w
ater. Triplicate 25 μL sam
ples of each diluted fraction w
ere m
ixed w
ith 1000 μL 
stains-all stock solution follow
ed by m
easurem
ent of absorption at 438 nm
. Triplicate standard sam
ples 
w
ere m
easured, m
ean absorbances plotted, and unknow
ns calculated typically using a linear regression (fig 
140 
3); in som
e cases 2
nd or 3
rd order polynom
ial curves w
ere used outside the range of linearity w
ith typical 
correlations of R
2 > 0.998.  
 
2.3 Inactivating H
IV
 in hum
an m
ilk w
ith an SD
S-loaded N
SD
S insert  
To determ
ine inactivation of cell-associated H
IV
 by SD
S released from
 the N
SD
S, hum
an m
ilk w
as spiked 
145 
w
ith H
9/H
IV
IIIB  cells (provided by the N
IH
 A
ID
S reagent program
 C
at. N
o. 400) to a final concentration of 
2.6 x 10
5 cells/m
l and w
as pum
ped through SD
S im
pregnated N
SD
S inserts using a near identical setup to 
that used to m
easure SD
S release kinetics, see section 2.2 (fraction collector: B
ioR
ad M
odel 2110, U
SA
). 
H
um
an m
ilk sam
ples w
ere provided by the M
others' M
ilk B
ank, V
alley M
edical C
entre (San Jose, 
C
alifornia, U
SA
). H
9/H
IV
IIIB  cells are self replicating cells that express H
IV
 (type-1 IIIB
), and have been 
150 
previously used to m
odel cell-associated H
IV
 (Lara et al., 2011; Y
am
aguchi et al., 2007). The cell content 
spiked in m
ilk w
as based on previously reported concentrations of betw
een 1 to 3255 infected cells per 10
4 
in m
ilk w
ith typical total cell concentrations in the first few
 days of life to be 10
6 cells/m
l (N
duati et al., 
1995; R
ousseau et al., 2004). Prior to being spiked in m
ilk, the cells w
ere centrifuged at 1500 R
PM
 for 5 
m
inutes and re-suspended in cell culture m
edia to rem
ove free virus. 5 m
l m
ilk fractions w
ere assayed for 
155 
H
IV
-infectivity using TZM
-bl cells in triplicate (provided by the N
IH
 A
ID
S reagent program
 C
at. N
o. 
8129). TZM
-bl cells are H
eLa clones genetically engineered to express C
C
R
5 and C
D
4 receptors and 
indicate H
IV
 infectivity via a luciferase reporter (M
ontefiori, 2005). Infectivity values w
ere calculated by 
com
paring them
 w
ith standard sam
ples of know
n infectivity for concentrations of H
9/H
IV
IIIB  cells in the 
sam
e m
ilk (Fig. 6a).  
160 
The concentrations of SD
S released into early m
ilk fractions, and the hum
an m
ilk itself, w
ere both found to 
disrupt the TZM
-bl reporter cells, preventing direct m
easurem
ent of H
IV
 infectivity in the fractions. 
Therefore, for all collected fractions, SD
S and m
ilk w
ere separated from
 H
9/H
IV
IIIB  cells 20 m
inutes after 
fraction collection, by 3 rounds of centrifugation and w
ashing in cell culture m
edium
 and phosphate 
buffered saline (PB
S). Prelim
inary experim
ents dem
onstrated this m
ethod rem
oved sufficient hum
an m
ilk 
165 
and SD
S at all release concentrations to prevent direct disruption of TZM
-bl cells w
ith the donor m
ilk used 
(data not show
n). This protocol also prevented H
IV
 inactivation by SD
S follow
ing N
SD
S treatm
ent, during 
subsequent sam
ple incubation w
ith TZM
-bl cells, w
hich w
ould not be representative of the conditions 
encountered by cell-associated H
IV
 passing through the N
SD
S in physiological breastfeeding conditions. 
100-150 μL sam
ples of m
ilk fractions w
ere diluted 1:10 (vol.) in cell culture m
edia in a 96-w
ell round 
170 
bottom
ed plate (# 3799, C
orning, U
SA
), centrifuged (1500 R
PM
 for 5 m
inutes at 15 °C
) and w
ashed tw
ice 
in PB
S, follow
ed by centrifugation and re-suspension of w
ashed H
9/H
IV
IIIB  cells in 100 µL culture  
m
edium
. C
ulture m
edium
 w
as based on D
ulbecco's M
odified Eagle M
edium
 H
igh G
lucose (D
M
EM
) 
(Invitrogen, U
SA
) and 15%
 (vol.) fetal bovine serum
 (Invitrogen, U
SA
). A
fter w
ashing, 25 µL of culture 
m
edium
, 25 µL w
ashed sam
ple and 50 µL TZM
-bl cells at 2 x 10
5 cells/ m
l w
ere added to flat bottom
ed 
175 
96-w
ell plates and incubated for 2 days at 36.5 °C
 and 5%
 C
O
2  (incubator: Sanyo, U
SA
). Sam
ples w
ere re-
suspended in culture m
edium
 and D
EA
E D
extran (30 µg/m
l) w
as added to TZM
-bl cells just prior to 
sam
ple addition at 2 µL per 1 x 10
5 cells/ m
l. A
 D
-Luciferin potassium
 salt (Therm
o Scientific, U
SA
) 
reagent m
ixture w
as added and lum
inescence read using a G
loM
ax®
 96 M
icroplate Lum
inom
eter 
(ProM
ega, U
SA
).  
180 
3.  R
ESU
LTS  
3.1 R
elease of the edible m
icrobicide SD
S from
 N
SD
S inserts 
The release of SD
S from
 a N
SD
S insert in a m
im
icked breastfeeding sim
ulation environm
ent w
as studied 
using the apparatus outlined in section 2.2 and Fig. 2d. This w
as perform
ed to provide evidence of the 
influence of the physiological variables w
ithin breastfeeding that could influence drug release from
 a 
185 
N
SD
S. Prelim
inary experim
ents determ
ined a suitable apparatus to m
im
ic drug release from
 a drug-loaded 
N
SD
S insert. C
onditions of m
ilk flow
 through an N
SD
S insert resem
bling breastfeeding w
ere achieved by 
m
aintaining the m
ilk at 37 °C
 and using a peristaltic pum
p to produce pulsed flow
 to sim
ulate the suction 
pressure created by a baby (Fig. 2d). D
uring breastfeeding, pulse rate and volum
e vary greatly, so a pulse 
rate of 60/m
in w
ith a volum
e of 0.07 m
l per pulse w
as chosen that lies w
ithin the typical range of a feeding 
190 
infant (Zoppou et al., 1997); this corresponds to a flow
 rate of 4.2 m
l/m
in. Total feeds have been reported 
to have a m
ean of 76 g (std. dev. 12.6 g) and a range of 0-240 g per feed, i.e. m
ean 74 m
l and range  
0-233 m
l per feed given a reported density of hum
an m
ilk of 1.03 g/m
l (K
ent et al., 2006). Test flow
 
conditions w
ere kept w
ithin these values. 
The SD
S insert form
ulation protocol w
as developed to produce an insert w
ith total load of 0.7 g SD
S,  a 
195 
sufficient quantity to release an effective m
icrobicidal concentration to rapidly inactivate H
IV
 in a feed (i.e. 
approxim
ately 0.1%
), w
hile keeping the total SD
S load w
ithin acceptable daily doses (H
artm
ann et al., 
2005, 2006a, 2006b).  
The spectrophotographic assaying m
ethod outlined in section 2.2 and Fig. 3 w
as used to detect SD
S for all 
release tests. W
hen flow
 conditions, insert loading, and m
ilk type and batch w
ere fixed, release kinetics in 
200 
replicate experim
ents w
ere highly reproducible confirm
ing that the apparatus is suitable for release studies 
(Fig. 4, Fig. 5 and data not show
n). G
iven the high variation in com
position of hum
an m
ilk betw
een 
individuals and even during feeds from
 the sam
e individual (D
aly et al., 1993; K
ent et al., 2006), release 
studies w
ere perform
ed w
ith com
m
ercial cow
’s and goat’s m
ilk w
hich is available in bulk quantities w
ith 
highly reproducible com
position.  
205 
In all conditions tested, the m
ajority (>70%
) of SD
S w
as released from
 non-w
oven inserts w
ithin 50 m
l. A
 
com
m
on release pattern presented itself: the highest am
ounts of SD
S releasing into early fractions, 
follow
ed by decreasing concentration over tim
e, indicating approxim
ately first order release kinetics. A
 
m
odel w
as fitted to the cum
ulative release data for each experim
ent to qualify this observation (see section 
3.4).  
210 
3.2 Effect of flow
 conditions and tem
perature and insert form
 on release kinetics 
The initial focus w
as to identify the principal release behavior of SD
S from
 the non-w
oven fiber over a 
range of flow
 conditions. This w
as intended to exam
ine the basic influence of fluid kinetics on release 
behavior, w
hich m
ay vary significantly from
 a feeding infant using the N
SD
S.  
The effect of m
ilk tem
perature upon release behavior w
as studied to provide evidence of the im
portance of 
215 
fluid tem
perature for future laboratory studies.  The release of SD
S from
 the non-w
oven fiber insert into 
hom
ogenized, pasteurized cow
’s m
ilk at 16 °C
 (laboratory tem
perature), w
as sim
ilar to that detected at 
37 °C
 (tem
perature of hum
an m
ilk)  into hom
ogenized, pasteurized cow
’s m
ilk (Fig. 4a and b). A
round  
70-100%
 release w
as detected after 30 m
l in all tests. This suggests that m
ilk tem
peratures betw
een 16 and  
37 °C
 m
ight not significantly influence SD
S release rate from
 the non-w
oven fiber. 
220 
The influence of tw
o types of flow
 conditions w
ere com
pared betw
een tests: the pulse rate (how
 quick the 
infant sucks) and the pulse volum
e (how
 m
uch m
ilk is extracted from
 the breast per suck); these w
ere 
controlled by altering the size of tubing used by the peristaltic pum
p and the operating speed. Tw
o test sets 
w
ere run using non-hom
ogenized pasteurized cow
’s m
ilk; (1) m
aintaining the pulse rate at 60 pulses/m
in 
and varying pulse volum
e at 0.02, 0.07 and 0.45 m
l/pulse and (2) m
aintaining the pulse volum
e at  
225 
0.07 m
l/pulse and varying the pulse rate to 40, 60 and 80 pulses/m
in. The release results dem
onstrated that 
SD
S w
as released into non-hom
ogenized cow
’s m
ilk at sim
ilar rates for all these flow
 rate conditions, w
ith 
>50%
 of release of the disc’s load after 20 m
l for all tests (Fig. 4c and d). SD
S concentrations of above 0.1 
w
t%
 SD
S (previously reported to be highly anti-viral – see 1. Introduction) w
ere seen for the tests in the 
first 20 m
l of m
ilk that passed through the non-w
oven fiber insert.   
230 
The influence of the non-w
oven fiber on SD
S release w
as determ
ined by com
parison to SD
S pow
der 
placed into the insert holder.  0.1 g of SD
S pow
der w
as used per test. Sim
ilar release patterns w
ere seen 
into m
ilk as w
ith non-w
oven fiber insert experim
ents (Fig. 4). R
elease from
 the flow
 cham
ber ranged from
 
40%
 to 70%
 after 50 m
l for 16 °C
 pasteurized and hom
ogenized cow
’s m
ilk and 80%
 for 37 °C
 for the 
sam
e m
ilk source (Fig. 4e).  
235 
3.3 Effect of m
ilk com
position on release kinetics 
The influence on release behavior due to m
ilk com
position w
as studied, using m
ilk from
 different anim
al 
sources and w
ith varying pasteurization and hom
ogenization.  A
nalysis of initial release behavior provided 
a suitable m
arker for the effect of different fluid types. A
pproxim
ately 100%
 of the insert load had released 
into non-hom
ogenized unpasteurized goat’s m
ilk w
ithin 10 m
l, 70-90%
 for hom
ogenized pasteurized cow
’s 
240 
m
ilk and 30-60%
 into the non-hom
ogenized pasteurized form
, suggesting progressively slow
er release into 
these respective fluids (Fig. 5). The m
ean volum
e needed for 50%
 release of the SD
S from
 the non-w
oven 
disc insert betw
een these 3 fluids w
as also com
pared, and goat’s m
ilk (average 1.4 m
l) induced 
significantly m
ore rapid release than both hom
ogenized pasteurized (5.1 m
l) (p < 0.05) and non-
hom
ogenized pasteurized (16.3 m
l) (p < 0.1) cow
’s m
ilk (using unpaired tw
o tailed t-tests).  The difference 
245 
in volum
e to 50%
 release into hom
ogenized com
pared to non-hom
ogenized cow
’s m
ilk w
as not significant 
(p > 0.05).  The observed difference in cow
’s and goat’s m
ilk release behavior indicates that m
ilk 
com
position significantly influences release kinetics 
3.4 M
odeling release behavior 
For an initial m
odel it w
as proposed that total drug release w
as dependent on the fraction of SD
S released 
250 
from
 the insert (Eq. (1)) for fixed flow
 and tem
perature conditions. 
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(1) 
q: 
V
olum
e of fluid passed through insert (m
l) 
M
r (q): 
M
ass fraction of SD
S release (relative to initial insert load) 
k
1 : 
C
onstant  
k
2 : 
C
onstant (m
l -1) 
Integrating from
 the start of the test until a volum
e, q, has passed through the insert gives Eq. (2):  
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(2) 
U
sing Eq. (2) for each release test k
1  and k
2  w
ere varied to optim
ize the least squares value using a 
com
putational non-linear regression analysis optim
ization algorithm
 (Tables 1. and 2.) (Softw
are: 
M
athem
atica - W
olfram
, IL U
SA
).  
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The 1
st order release kinetics m
odel presented R
2 > 0.969 for all tests apart from
 one w
ith the highest flow
 
rates, w
ith R
2 at 0.933 (Table 1.). This indicates that for m
ost flow
 conditions the release behavior is w
ell 
m
odeled by 1
st order release kinetics. For non-w
oven fiber tests under the sam
e flow
 conditions (Table 2.) 
the constant k
2 w
as noticeably higher in goat’s m
ilk (0.416-0.522) com
pared to non-hom
ogenized cow
’s 
m
ilk (0.141-0.181) to hom
ogenized cow
’s m
ilk (0.036-0.069). The m
ean k
2 values for each fluid w
ere 
260 
statistically different betw
een all fluids (p < 0.05) using unpaired, tw
o tailed t-tests. k
2 , w
hich indicates rate 
of release, w
as highest for the goat’s m
ilk, w
here SD
S release w
as m
ost rapid. k
1  reflects the total 
m
axim
um
 release expected by 1
st order release kinetics. G
iven the total cum
ulative release reaching  
70-100%
 w
ithin 50 m
l for m
ost tests, k
1  values derived by regression analysis w
ere found to be close to 1. 
Further tests are needed to expand the m
odel and to determ
ine w
hich com
ponent(s) of m
ilk influence the 
265 
rate of release.  
3.5 H
IV
 inactivation by a SD
S loaded N
SD
S insert 
For the final elem
ent of this proof of concept study the reduction of cell-associated H
IV
 by SD
S w
as 
studied using the sam
e apparatus and test conditions as the release studies, but using hum
an m
ilk. G
iven 
the anti-viral concentrations of SD
S found to release into various m
ilk types in early fractions, it w
as 
270 
predicted that sim
ilar release w
ould be expected in hum
an m
ilk, and thus the N
SD
S should significantly 
reduce the am
ount of H
IV
 infectivity at least in the first portion of m
ilk passed through the insert.  
It has been previously argued that cell-associated H
IV
 m
ay have the predom
inant role in M
TCT of H
IV
 in 
breastfeeding (R
ousseau et al., 2004) so cell associated H
IV
 w
as used in these virology studies. H
9/H
IV
IIIB  
cells w
ere used as a m
odel of cell-associated H
IV
. The cells w
ere spiked into hum
an m
ilk to m
im
ic m
ilk 
275 
from
 H
IV
 positive m
others, and w
ere then passed through SD
S-loaded N
SD
S inserts at 60 pulses/m
in and 
0.07 m
l/pulse (used in release tests and typical of infant feeding conditions, see section 3.1). TZM
-bl cells 
w
ith luciferase reporter genes w
ere used to m
easure the infectivity of H
9/H
IV
IIIB  cells before and after the 
tests. Since exposure of TZM
-bl cells to both hum
an m
ilk and SD
S can artificially reduce the apparent 
infectivity of H
9/H
IV
IIIB  cells, an assay w
as developed that allow
ed m
easurem
ent of inactivation of cell-
280 
associated H
IV
 by the N
SD
S, w
hereby both hum
an m
ilk and SD
S w
ere rem
oved 20 m
inutes after 
collection follow
ed by m
easurem
ent of H
IV
 infectivity (see section 2.3).  
W
hen know
n doses of H
9/H
IV
IIIB  cell sam
ples w
ere assayed w
ith this m
ethod using TZM
-bl cells, 
H
9/H
IV
IIIB  cell concentrations betw
een 0.26 x 10
4 – 26 x 10
4 cells/m
l w
ere quantitatively detected, 
indicating a sensitive assay of H
IV
 infectivity (Fig. 6a). R
elative H
IV
 infectivity levels in sam
ples of 
285 
N
SD
S-treated m
ilk w
ere then determ
ined by com
paring the m
easured lum
inescence from
 TZM
-bl cells 
exposed to test sam
ples w
ith the calibration data in Fig. 6a. U
sing this m
ethod, it w
as found that treatm
ent 
of H
IV
-spiked hum
an m
ilk w
ith the N
SD
S SD
S-loaded insert resulted in a significant reduction in the 
m
ean correlated infected cell content of 3 tests, com
pared to input cell content (Fig. 6b). A
verage infectious 
cell content reductions w
ere significant at the follow
ing levels: M
ore than 2 log reduction for 0-5 m
l  
290 
(p < 0.0001), 1.5 log reduction for 5-10 m
l (p < 0.0001) and 0.6 log reduction for 10-15 m
l (p < 0.05) 
(using paired single tailed t-tests). A
 0.4 log reduction for 15-20 m
l, 0.4 log reduction for 20-25 m
l and  
0.3 log reduction for 25-30 m
l in m
ean infected cell content w
as observed but these reductions w
ere not 
significant (p  > 0.05). The individual infectious cell content in each volum
e fraction is illustrated in Fig. 
6b. The sm
all variation in reduction of infectivity betw
een repeat tests is likely due biological variations in 
295 
inactivation betw
een tests, given the sm
all variance observed betw
een replicate H
IV
 infectivity assays of 
individual fractions (Fig. 6b). 
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4.1 D
rug release into m
ilk from
 the N
SD
S 
Param
eters that are expected to influence release kinetics of an A
PI from
 a N
SD
S are: drug form
, support 
300 
m
aterial/excipients, flow
 conditions and solvent type. For this study w
here flow
 conditions and m
ilk type 
w
ere changed the greatest variation in release behavior w
as seen betw
een the differing m
ilk types, w
ith 
goat’s m
ilk producing the m
ost rapid SD
S release rate. U
nderstanding in detail the effect of m
ilk 
com
position on release kinetics w
ill be im
portant for controlled release into hum
an m
ilk, w
hich is know
n 
to have highly variable com
position; for exam
ple during a typical feed, the fat content can increase by up to 
305 
3-fold (D
aly et al., 1993).  
In order to obtain consistent drug release betw
een m
others despite their varying m
ilk content, it m
ay be 
necessary to produce an insert form
ulation that w
ould allow
 for flow
 rate-independent release kinetics for 
various m
ilk com
positions possible in feeding. Further form
ulation m
ethods should be considered for SD
S 
and other A
PIs. They could include m
odifying or changing the current soaking im
pregnation m
ethod onto 
310 
the fiber or using a different support m
aterial such as a rapidly disintegrating tablet or a soluble polym
er 
film
. Prelim
inary tests dem
onstrated that addition of hydroxym
ethyl propyl cellulose into the SD
S insert 
during form
ulation m
ay result in slow
er SD
S release into m
ilk and reduce the initial high release that 
appears to be highly com
position dependent (unpublished observations). A
lternatively, SD
S or other A
PIs 
m
ight be incorporated in the fiber during m
anufacturing, to further control release as seen in related studies 
315 
(C
ui et al., 2006).  
The first-order cum
ulative release m
odel presented fitted our observed data w
ell, and the constants derived 
by regression analysis supported the observation that the m
ajority of drug is released for m
ost tests w
ithin 
50 m
l, and that m
ilk com
position significantly influences rate of release. H
ow
ever this sim
ple m
odel m
ay 
not encom
pass all the factors influencing release from
 the non-w
oven fiber, especially at higher flow
 rates 
320 
w
here the m
odel fitted least w
ell; further w
ork is required to refine the m
odel. W
e postulate that a 
com
bination of dissolution phenom
ena and solid and hydrated particulate release from
 the fibers govern 
SD
S release from
 fibers.  
4.2 V
iral inactivation in hum
an m
ilk 
There w
as a high inactivation of cell-associated virus in early fractions (0-10 m
l) of hum
an m
ilk passed 
325 
through the N
SD
S SD
S-insert (> 99%
), follow
ed by a m
uch sm
aller reduction in later fractions. The 
reported threshold of rapid H
IV
 inactivation (> 0.1 w
t%
) also occurred w
ithin the first 10 m
l of release for 
goat’s m
ilk but then rapidly decreased to below
 reported m
icrobicidal concentrations (H
artm
ann et al., 
2006a, 2006b, 2005). This suggests that the initial high release behavior of SD
S observed in goat’s m
ilk 
m
ay also have occurred w
ith hum
an m
ilk and therefore goat’s m
ilk m
ay be a suitable m
im
ic for use in 
330 
N
SD
S release studies. Further w
ork is needed to understand w
hat com
ponents affect SD
S release and 
dissolution, and how
 m
ilk com
position affects release kinetics before a suitability-of-use analysis can be 
m
ade.   
The im
portance of the release kinetics of SD
S into H
IV
 infected m
ilk for prevention of M
TCT can only be 
speculated about at this point. M
TCT of H
IV
 in breastfeeding is com
plex and incom
pletely understood. 
335 
Transm
ission m
ay occur either through the free virus or cell-associated virus, w
ith possible sites of 
transm
ission including the m
ucosal surfaces of the tonsils and gut (C
avarelli and Scarlatti, 2011). Thus the 
SD
S release rate into m
ilk m
ay alter transm
ission rates depending on w
here anti-viral concentrations of 
SD
S in the digestive system
 reside during the feed. The proof of concept data in this paper should provide 
an indication of how
 cell-associated H
IV
 could be inactivated by SD
S in a physiological environm
ent. In 
340 
vivo SD
S m
ay act on both free virus and infected cells during their passage through the digestive system
, 
and SD
S released into early fractions m
ay subsequently m
ix w
ith infected m
ilk consum
ed later in the feed. 
This w
ould lead to a higher reduction of H
IV
 infectivity than that seen in this sim
plified study.  Further 
study w
ill be required to better predict the effectiveness of a given N
SD
S m
icrobicide form
ulation on 
preventing infection. O
ne key advantage of SD
S over other anti-viral com
pounds is its ability to rapidly 
345 
inactivate H
IV
 (H
artm
ann et al., 2005); this rapid inactivation m
ay reduce viral load in infected m
ilk before 
it even reaches proxim
al sites of infection such as the oral m
ucosal tissues of the infant. 
The incorporation of im
m
obilized m
icrobicidal surfaces w
ithin the N
SD
S m
ay also be a viable 
consideration for preventing M
TCT of H
IV
 specifically by inactivating virus during passage through the 
N
SD
S. For exam
ple, viral inactivation using copper-based fibers has also been considered in a 
350 
breastfeeding device (B
orkow
 et al., 2011, 2008). This could be com
bined w
ith m
icrobicide release to 
potentially increase viral inactivation using a N
SD
S.  
4.3 Future uses of the N
SD
S 
The acceptability of a N
SD
S to breastfeeding m
others m
ust be carefully assessed prior to use.  For its 
specific use in preventing M
TCT of H
IV
 during breastfeeding a study w
as conducted in K
enya. M
others 
355 
and stakeholders involved in deciding infant feeding practices w
ere questioned, and gave positive feedback 
about the potential use of a N
SD
S to prevent H
IV
 transm
ission in feeding (Israel-B
allard et al., 2010). 
For any specific application, careful consideration w
ill be needed to determ
ine if a disposable single use 
device or a re-useable one, w
ith a replaceable drug-loaded insert w
ould be m
ost suitable. A
lthough a re-
usable N
SD
S w
ould be m
ore sustainable and low
er cost, in low
-resource settings w
here sanitation 
360 
equipm
ent m
ay be lim
ited, the feasibility of ensuring hygienic device re-use w
ill have to be carefully 
considered. 
A
side from
 SD
S delivery a w
ide range of individual or com
binations of m
edicinal substances could be 
delivered to infants using the N
SD
S, including drugs such as antibiotics and antim
alarials, or vitam
ins, 
nutrients and probiotics. Sim
ilar inserts could be incorporated into m
odified bottle teats, allow
ing equally 
365 
effective drug delivery to infants fed w
ith form
ula or expressed m
ilk via a bottle.  
U
sing a N
SD
S to deliver agents other than m
icrobicides w
ill generally require sim
ple direct A
PI release 
rather than potentially sustained release, w
ith the prim
ary focus to ensure full dose release w
ithin a typical 
feed. Taste, solubility and the effect of the form
ulation on the nutrition value of the m
ilk w
ould be prim
ary 
considerations, and alternative insert form
s such as tablets should be considered.  
370 
Potential advantages of the N
SD
S over other infant drug delivery routes and devices include ease of use 
and precise dosing com
pared w
ith drops or spoon-fed liquids. A
lternatives to parenteral delivery are 
particularly im
portant for frequently adm
inistered drugs because of the burden on trained healthcare 
w
orkers, the risks associated w
ith needle use, and to avoid pain associated w
ith injecting infants. For som
e 
oral A
PIs, m
ilk m
ay m
ask taste, im
proving acceptability for the infant. Furtherm
ore, for labile A
PIs a dried 
375 
form
ulation offers im
proved stability over liquid form
ulations. D
rug adm
inistration during breastfeeding 
m
ay also increase the bioavailability of som
e drugs (Charkoftaki et al., 2010). 
 A
dditional benefits of the N
SD
S in low
-resource healthcare settings include sim
plicity, low
 cost 
production, a low
 level of training needed for correct dosing, potential for a single-use disposable device 
avoiding requirem
ent for sterilization, and a robust dry form
ulation for therm
ostable distribution.  M
ost 
380 
im
portantly, w
ith reducing M
TCT of H
IV
, the N
SD
S is designed to be com
patible w
ith breastfeeding, 
w
hich is often the safest m
ethod of infant feeding even w
hen the m
other is infected (B
rahm
bhatt and G
ray, 
2003).  
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A
 sustained release of the edible m
icrobicide SD
S into H
IV
 infected m
ilk during breastfeeding from
 a 
385 
N
SD
S placed over the m
other’s breast, is proposed to be an effective m
ethod for oral delivery of 
m
icrobicides to prevent M
TCT of H
IV
. This study has dem
onstrated that a N
SD
S can deliver SD
S into 
m
ilk from
 a non-w
oven fiber insert at non-toxic m
icrobicidal concentrations. It has also dem
onstrated that 
SD
S release using the N
SD
S is capable of rapidly inactivating significant am
ounts of cell-associated H
IV
 
in hum
an m
ilk. The N
SD
S is especially valuable for use in developing countries w
here no safer alternative 
390 
to breastfeeding exists. Future w
ork is needed to fully understand the effects of m
ilk com
position on 
release kinetics. M
odifying the non-w
oven fiber com
position, the addition of cellulose based com
pounds 
onto the fiber, or the addition of m
icrobicides and cellulose in fiber construction, m
ay enable controlled 
release patterns. W
ith better understanding of the sites of transm
ission in breastfeeding these m
ethods 
could be adapted to m
axim
ize reduction of M
TCT of H
IV
.  
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T
ables: 
410 
T
able 1.  
Insert 
Pasteurized 
H
om
ogenized 
Fluid 
Tem
p 
(° C
) 
Pulse R
ate 
(pulses/m
in) 
Pulse 
V
olum
e 
(m
l/pulse) 
Total 
release 
(/initial 
load) 
k
1  
k
2 
(m
l -1) 
R
2 
G
raph 
R
ef 
Fiber 
x 
x 
16 
60 
0.07 
0.81 
0.800 
0.139 0.990 
4a 
Fiber 
x 
x 
16 
60 
0.07 
0.77 
0.750 
0.157 0.969 
 
Fiber 
x 
x 
37 
60 
0.07 
0.80 
0.794 
0.185 0.984 
4b 
Fiber 
x 
x 
37 
60 
0.07 
0.86 
0.870 
0.141 0.988 
 
Fiber 
x 
 
37 
60 
0.02 
0.83 
0.824 
0.156 0.984 
4c 
Fiber 
x 
 
37 
60 
0.07 
1.14 
1.180 
0.069 0.994 
 
Fiber 
x 
 
37 
60 
0.45 
0.87 
0.803 
0.124 0.933 
 
Fiber 
x 
 
37 
80 
0.07 
0.97 
0.933 
0.097 0.971 
4d 
Fiber 
x 
 
37 
60 
0.07 
1.14 
1.180 
0.069 0.994 
 
Fiber 
x 
 
37 
40 
0.07 
0.90 
0.879 
0.252 0.987 
 
Flow
 
C
ell 
x 
x 
16 
60 
0.07 
0.46 
0.439 
0.098 0.992 
4e 
Flow
 
C
ell 
x 
x 
16 
60 
0.07 
0.70 
0.666 
0.075 0.984 
 
Flow
 
C
ell 
x 
x 
37 
60 
0.07 
0.93 
0.900 
0.057 0.991 
 
Sum
m
ary of SD
S release experim
ents using cow
’s m
ilk w
ith varying flow
 conditions. Fitted m
odel param
eters 
to a first-order release kinetic m
odel according to Equ. (2) also displayed.  
 
T
able 2. 
M
ilk 
Pasteurized 
H
om
ogenized 
Total 
release 
(/initial 
load) 
k
1  
k
2 
(m
l -1) 
R
2 
G
raph 
R
ef 
C
ow
 
x 
x 
0.80 
0.794 
0.185 
0.984 
5a 
C
ow
 
x 
x 
0.86 
0.870 
0.141 
0.988 
 
C
ow
 
x 
x 
1.04 
1.026 
0.183 
0.994 
 
C
ow
 
x 
 
1.14 
1.180 
0.069 
0.994 
5b 
C
ow
 
x 
 
0.79 
0.906 
0.036 
0.984 
 
C
ow
 
x 
 
0.76 
0.753 
0.065 
0.988 
 
G
oat 
 
 
1.07 
1.057 
0.416 
0.978 
5c 
G
oat 
 
 
1.14 
1.149 
0.522 
0.989 
 
G
oat 
 
 
1.02 
1.030 
0.452 
0.995 
 
Sum
m
ary of SD
S release experim
ents using cow
’s and goat’s m
ilk for constant flow
 conditions.  
Fluid tem
perature 37° C
, 60 pulses/m
in, 0.07 m
l/pulse and SD
S-fibre insert. Fitted m
odel param
eters to a first-
order release kinetic m
odel according to Equ. (2) also displayed. 
 
 Figure legends: 
G
raphical A
bstract: 
415 
C
ross sectional diagram
 of m
ilk leaving breast passing through nipple shield delivery system
 insert. 
Fig. 1. N
ipple shield delivery system
 for oral drug delivery to breastfeeding infants  
(Im
ages provided courtesy of http://justm
ilk.org) (a) N
on-w
oven fiber inserts. (b) D
em
onstration of 
blister pack containing replaceable inserts. (c) A
 m
odified silicone nipple shield adapted to hold inserts in 
place during breastfeeding (prototype, not for clinical use).  
420 
Fig. 2. M
ethods for studying SD
S release into m
ilk in pulsed flow
 conditions  
(a) The fiber insert sealed into the housing w
ithin an o-ring. (b) The assem
bled housing. (c) SD
S-
im
pregnated non-w
oven fiber insert housed w
ithin an o-ring. (d) D
iagram
 of rig used to deliver pulsed 
flow
s of m
ilk through the filter housing and collect fractions to be m
easured for SD
S content/cell 
associated H
IV
 infectivity. 
425 
Fig. 3. Sim
ple, rapid m
easurem
ent of SD
S concentration in m
ilk using stains-all dye 
The absorbance at 438nm
 w
as m
easured for know
n concentrations of SD
S dissolved either in (a) w
ater or 
m
ilk subsequently diluted in (b) 1:10 w
ater dilution or (c) 1:100 w
ater dilution. A
 clear linear relationship 
betw
een absorbance and SD
S concentration is apparent for each fixed dilution ration allow
ing accurate 
m
easurem
ent of SD
S release into m
ilk over a range of concentrations. D
ata representative of >20 
430 
experim
ents; fresh standard curves w
ere prepared for every release experim
ent using the sam
e batch and 
type of m
ilk tested to determ
ine SD
S concentrations. The standard error of repeat m
easurem
ents is 
displayed. 
Fig. 4. Effect of SD
S form
, tem
perature and flow
 on release kinetics 
Pasturised cow
’s m
ilk w
as flow
ed through SD
S loaded onto non-w
oven fibre discs (a-d) or SD
S pow
der (e) 
435 
and SD
S concentration determ
ined. (a, b) The effect of tem
perature on release at a flow
 rate of 4.3 m
l/m
in 
and pulse rate 60 pulses/m
in w
as determ
ined. (c) The effect on release of varying pulse volum
e at a fixed 
pulse rate of 60 pulses/m
in w
as determ
ined. (d) The effect of varying pulse rate for a fixed pulse volum
e of 
0.07 m
l/m
in w
as determ
ined. (e) The release of SD
S in pow
der form
 at 16°C
 and 37°C
 at a flow
 rate of 4.3 
m
l/m
in and pulse rate 60 pulses/m
in w
as m
easured. D
ata displayed as (i) concentration of SD
S in 
440 
individual collected 1 m
l fractions and (ii) cum
ulative SD
S release relative to input SD
S load. In all cases, 
each set of sym
bols represents an individual release experim
ent,  w
ith the m
ean of triplicate m
easurem
ents 
of SD
S concentrations for each fraction show
n. 
Fig. 5. Effect of m
ilk type on SD
S release kinetics 
The release of SD
S from
 loaded non-w
oven fibre discs during pulsed flow
 into (a) hom
ogenised pasturised 
445 
cow
’s m
ilk, (b) non-hom
ogenised cow
’s m
ilk and (c) non-hom
ogenised unpasturised goat’s m
ilk w
as 
m
easured w
ith a flow
 rate of 4.3m
l/m
in and pulse rate of 60/m
in. D
ata are displayed as concentration of 
SD
S in collected 1 m
l fractions (i) and cum
ulative SD
S release relative to input disc load (ii). In all cases, 
each set of sym
bols represents an individual release experim
ent, w
ith the m
ean of triplicate m
easurem
ents 
of SD
S concentrations for each fraction show
n. 
450 
Fig. 6. R
eduction in H
IV
 infectivity in hum
an m
ilk after flow
 through SD
S-loaded N
SD
S insert 
(a) Calibration curve used to determ
ine H
9/H
IV
IIIB  cell content in m
ilk; TZM
-bl reporter cells w
ere 
infected w
ith a range of H
9/H
IV
IIIB  cell concentrations in m
ilk and assayed for infection by lum
inescence 
reporter activity (relative lum
inescent units, R
LU
). (b) TZM
-bl cell infection by H
9/H
IV
IIIB  cells in m
ilk 
w
as m
easured after passage of the m
ilk plus cells through SD
S-containing non-w
oven fiber inserts. 
455 
R
eporter activity (infectivity) is plotted as the equivalent num
ber of H
9/H
IV
IIIB  cells, calculated using the 
calibration assay show
n in (a). 3 repeat experim
ents w
ere perform
ed and individual data plotted for all 
experim
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